TAGRISSO- New Indications for Non Small Cell Lung Cancer!

---

---

Adjuvant TAGRISSO was approved with breakthrough therapy designation status as adjuvant therapy after tumor resection in adult patients with non‑small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test—this is unparalleled news for resectable EGFRm NSCLC patients.

---

To see if this mediation is right for you, please contact our office at 972-548-9690 to speak to one of our physicians.